doi:10.1053/j.gastro.2014.11.039
Gut microbiota-derived tryptophan metabolites maintain gut and systemic homeostasis

Disclosures: Joanne Hsieh: Gordian Biotechnology: Employee, Vinay Kartha: Nothing to Disclose, Hikaru Miyazaki: Nothing to Disclose, Christopher Carrico: Nothing to Disclose, Linda Chio: Gordian Biotechnology: Employee, Gordian Biotechnology: Stock privately held company, Daniel Fuentes: Nothing to Disclose, Dimitry Popov: Nothing to Disclose, Ian Driver: Nothing to Disclose, Chris Towne: Nothing to Disclose, Francisco LePort: Nothing to Disclose, Martin Borch Jensen: Nothing to Disclose 2067 PHARMACOKINETICS, SAFETY AND EFFICACY OF THE NOVEL NON-BILE ACID FXR AGONIST FXR314 IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: RESULTS FROM A PHASE 2 STUDY Eric Lawitz 1 Kathryn Jean Lucas 2 Kris Kowdley 3 Naim Alkhouri 4 Stephen Harrison 5 Fabrice Piu 6 , 1 Texas Liver Institute, 2 Diabetes & Endocrinology Consultants, PC, 3 Liver Institute Northwest, 4 Arizona Liver Health, 5 University of Oxford, 6 Organovo, Inc Background Farnesoid X receptor (FXR) agonism has demonstrated clinical utility for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) but clinical development has been hampered by limited efficacy and adverse events (pruritus, dyslipidemia)

Choose products with realistic claims and clear usage directions
Chapman KA, Gropman A, MacLeod E, Stagni K, Summar ML, Ueda K, et al
How often can I get B12 shots